{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T13:50:29Z","timestamp":1767016229414,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The present case contributes to the limited literature on central nervous system involvement of blastic plasmacytoid dendritic cell neoplasm (BPDCN).\u00a0<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation\u00a0<\/jats:title>\n                <jats:p>A 63-year-old male presented to the department of neurology with a three-day history of rapidly progressing headache, fatigue, and confusion. Physical examination revealed multiple bruise-like skin lesions. Initial laboratory workup raised suspicion of acute leukemia, and a brain computer tomography identified several hyperdense processes. A bone marrow biopsy gave the diagnosis BPDCN, a rare and aggressive hematologic malignancy derived from plasmacytoid dendritic cells with a poor prognosis. Lumbar puncture showed not only signs of BPDCN, but also cerebral toxoplasmosis, thus providing a differential diagnosis. Despite intensive systemic and intrathecal chemotherapy, the patient died 25\u00a0days later due to multi-organ failure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The exact incidence of BPDCN is unknown and perhaps underestimated but may account for 0.5 \u2013 1% of all hematological malignancies. The median age at onset is 60 to 70\u00a0years, and most patients are men. Cutaneous lesions are the most frequent clinical manifestation at diagnosis. Other symptoms present at time of diagnosis or during disease progression include lymphadenopathy, splenomegaly and cytopenia caused by bone marrow involvement. Although the majority of BPDCN patients have no symptoms or signs of central nervous system involvement, plasmacytoid dendritic cells have been detected in the cerebrospinal fluid in more than 50%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This case highlights the importance of considering hematological malignancies as a differential diagnosis in patients developing acute neurological symptoms and raises suspicion of a possible association between toxoplasmosis and hematological malignancies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-022-02748-5","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T10:03:51Z","timestamp":1656065031000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Blastic plasmacytoid dendritic cell neoplasm and cerebral toxoplasmosis: a case report"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6642-2917","authenticated-orcid":false,"given":"Anna Maria","family":"Florescu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4537-2505","authenticated-orcid":false,"given":"Anne Louise T\u00f8lb\u00f8ll","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik Vedel","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Tolnai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lene Dissing","family":"Sj\u00f6","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja Lohmann","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1118-9665","authenticated-orcid":false,"given":"Mohammad Al-Mahdi","family":"Al-Karagholi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,24]]},"reference":[{"key":"2748_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1182\/asheducation-2016.1.16","volume":"2016","author":"JM Sullivan","year":"2016","unstructured":"Sullivan JM, Rizzieri DA. Treatment of blastic plasmacytoid dendritic cell neoplasm. Hematology. 2016;2016:16\u201323.","journal-title":"Hematology"},{"key":"2748_CR2","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.1182\/bloodadvances.2020002474","volume":"4","author":"K Laribi","year":"2020","unstructured":"Laribi K, et al. Blastic plasmacytoid dendritic cell neoplasms: Results of an international survey on 398 adult patients. Blood Adv. 2020;4:4838\u201348.","journal-title":"Blood Adv"},{"key":"2748_CR3","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Special Edition","author":"SH Swerdlow","year":"2017","unstructured":"Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Special Edition. 4th ed. 2017.","edition":"4th"},{"key":"2748_CR4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/bjd.12412","volume":"169","author":"F Julia","year":"2013","unstructured":"Julia F, et al. Blastic plasmacytoid dendritic cell neoplasm: Clinical features in 90 patients. Br J Dermatol. 2013;169:579\u201386.","journal-title":"Br J Dermatol"},{"key":"2748_CR5","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1111\/jdv.16215","volume":"34","author":"MC Br\u00fcggen","year":"2020","unstructured":"Br\u00fcggen MC, et al. Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre study. J Eur Acad Dermatology Venereol. 2020;34:1489\u201395.","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"2748_CR6","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1182\/blood.V99.5.1556","volume":"99","author":"J Feuillard","year":"2014","unstructured":"Feuillard J, et al. Clinical and biologic features of CD4 + CD56 + malignancies. Blood. 2014;99:1556\u201363.","journal-title":"Blood"},{"issue":"4","key":"2748_CR7","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1080\/10428190500353216","volume":"47","author":"JG Rossi","year":"2006","unstructured":"Rossi JG, et al. Acute leukemia of dendritic cell lineage in childhood: Incidence, biological characteristics and outcome. Leuk Lymphoma. 2006;47(4):715\u201325. https:\/\/doi.org\/10.1080\/10428190500353216.","journal-title":"Leuk Lymphoma"},{"key":"2748_CR8","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/leu.2012.120","volume":"26","author":"JJM Van Dongen","year":"2012","unstructured":"Van Dongen JJM, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26:1908\u201375.","journal-title":"Leukemia"},{"key":"2748_CR9","doi-asserted-by":"publisher","first-page":"10174","DOI":"10.18632\/oncotarget.7101","volume":"7","author":"L Mart\u00edn-Mart\u00edn","year":"2016","unstructured":"Mart\u00edn-Mart\u00edn L, et al. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget. 2016;7:10174\u201381.","journal-title":"Oncotarget"},{"unstructured":"Facchetti F, Petrella T, Pileri SA, et al. Blastic plasmacytoid dendritic cell neoplasm. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Re; 2017. p. 174\u20137.","key":"2748_CR10"},{"key":"2748_CR11","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/bjh.14146","volume":"174","author":"L Pagano","year":"2016","unstructured":"Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: Diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174:188\u2013202.","journal-title":"Br J Haematol"},{"key":"2748_CR12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.bbi.2019.01.026","volume":"79","author":"KS Burgdorf","year":"2019","unstructured":"Burgdorf KS, et al. Large-scale study of Toxoplasma and Cytomegalovirus shows an association between infection and serious psychiatric disorders. Brain Behav Immun. 2019;79:152\u20138.","journal-title":"Brain Behav Immun"},{"key":"2748_CR13","first-page":"1","volume":"8","author":"ZD Wang","year":"2017","unstructured":"Wang ZD, et al. Toxoplasma gondii infection in immunocompromised patients: A systematic review and meta-analysis. Front Microbiol. 2017;8:1\u201312.","journal-title":"Front Microbiol"},{"key":"2748_CR14","doi-asserted-by":"publisher","first-page":"494","DOI":"10.23907\/2017.042","volume":"7","author":"WT Harrison","year":"2017","unstructured":"Harrison WT, Hulette C. Cerebral Toxoplasmosis: A Case Report with Correlation of Radiographic Imaging, Surgical Pathology, and Autopsy Findings. Acad Forensic Pathol. 2017;7:494\u2013501.","journal-title":"Acad Forensic Pathol"},{"key":"2748_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.00242","volume":"10","author":"D Schl\u00fcter","year":"2019","unstructured":"Schl\u00fcter D, Barragan A. Advances and challenges in understanding cerebral toxoplasmosis. Front Immunol. 2019;10:1\u201313.","journal-title":"Front Immunol"},{"key":"2748_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2147\/BLCTT.S132060","volume":"7","author":"AM Trottier","year":"2017","unstructured":"Trottier AM, Cerquozzi S, Owen CJ. Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects. Blood Lymphat Cancer Targets Ther. 2017;7:85\u201393.","journal-title":"Blood Lymphat Cancer Targets Ther"},{"key":"2748_CR17","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1017\/S0950268818002194","volume":"146","author":"N Kalantari","year":"2018","unstructured":"Kalantari N, et al. Association between Toxoplasma gondii exposure and paediatrics haematological malignancies: A case-control study. Epidemiol Infect. 2018;146:1896\u2013902.","journal-title":"Epidemiol Infect"},{"key":"2748_CR18","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/hon.2147","volume":"33","author":"R Paluri","year":"2015","unstructured":"Paluri R, Nabell L, Borak S, Peker D. Unique presentation of blastic plasmacytoid dendritic cell neoplasm: a single-center experience and literature review. Hematol Oncol. 2015;33:206\u201311.","journal-title":"Hematol Oncol"},{"key":"2748_CR19","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1182\/blood-2012-08-448613","volume":"121","author":"D Roos-Weil","year":"2013","unstructured":"Roos-Weil D, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: A retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013;121:440\u20136.","journal-title":"Blood"},{"key":"2748_CR20","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","volume":"380","author":"N Pemmaraju","year":"2019","unstructured":"Pemmaraju N, et al. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med. 2019;380:1628\u201337.","journal-title":"N Engl J Med"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02748-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02748-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02748-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T10:07:40Z","timestamp":1656065260000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02748-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,24]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2748"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02748-5","relation":{},"ISSN":["1471-2377"],"issn-type":[{"type":"electronic","value":"1471-2377"}],"subject":[],"published":{"date-parts":[[2022,6,24]]},"assertion":[{"value":"22 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have ethical conflicts to disclose. Written informed consent was obtained from the patient\u2019s relative regarding the patient\u2019s participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient\u2019s relative regarding publication of this case report and any accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Mohammad Al-Mahdi Al-Karagholi has received personal fee for lecturing\/advisory board from Novartis and Electro Core.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"233"}}